Share Name Share Symbol Market Type Share ISIN Share Description
Akers Biosciences, Inc LSE:AKR London Ordinary Share US00973E1029 COM SHS NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 107.50p 95.00p 120.00p 107.50p 107.50p 107.50p 2,705.00 07:57:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 1.4 -6.5 -122.8 - 7.79

Akers Biosciences Share Discussion Threads

Showing 3776 to 3791 of 3800 messages
Chat Pages: 152  151  150  149  148  147  146  145  144  143  142  141  Older
DateSubjectAuthorDiscuss
01/2/2017
13:10
Record pifa sales in h2, coupled with a significantly lower cost base ($4.6m vs $7m cash breakeven sales rate) and a near historic low valuation - probably never been a better time to buy.
wigwammer
01/2/2017
07:37
expected profit warning Approximately $0.5 million in sales of these products to China were recorded in 2016. This was significantly below expectations of sales to China in the period as the balance of the $2.5 million order from NovoTek Therapeutics Inc. ("NovoTek"), the Company's exclusive distributor for these products in China, announced in March 2016, has not yet been released. Sad Best salvage as it stands is to sell the flagship product and then file for a class action against the directors and professionals
norbus
22/1/2017
09:29
"If they needed funding - which they clearly did"Perhaps they didn't know if the large Chinese order would materialise. With another $1.5m-$2m in hand perhaps they would not have needed to ask for the money, or could at least have scaled it back.
wigwammer
21/1/2017
09:32
The initial S3 form submitted 24 October 2016 included "On October 18, 2016, the last reported sale price of our common stock on the Nasdaq Capital Market was $3.30 per share". If they needed funding - which they clearly did - then why did Gormally not simply get the funds secured at that time when the share price had been trading above $3 for around 3 months? Even with, say, a hefty 20% discount they could still probably have placed at around $2.50. The proposed placing at $1.20 suggests to me that he is either a "friend of Wally", looking after persons other than current shareholders or that there is little appetite for the stock (ie belief in what he / the management are doing); was it determined whether any of the management took part in the offering?
mcmather
20/1/2017
11:32
Sure.In other news, mid price now down to the usd quote level, and around the issue price.Seems to be a few buyers coming in.
wigwammer
19/1/2017
23:50
Tbh saying that sort of thing on a chat board doesn't definitively define anyone, and I feel bad about suggesting it.But it's still a stupid thing to say.I'll lose all my money here but I won't get dragged into that sh1te.
wigwammer
19/1/2017
15:36
Classy Norbus, Real CLASSY.
qazwsxedc69
17/1/2017
08:24
Must be still collecting the issue money; Does not feel right
norbus
16/1/2017
12:03
Lots of words, vaguely pertaining to the (endlessly repeated) point that you don't like Dr Akers.Beyond that, as a previous poster suggested, nothing of much use.
wigwammer
16/1/2017
11:06
Nobody throws good money after bad unless they were great stock pickers like Neil Woodford who is looking to recruit; With a closing date last Thursday, I suppose they are cutting the application due to massive over subscription and attention to the-inauguration balls invitations on offer to The Akers
norbus
16/1/2017
10:38
"a constructive comment" (or at least something pertaining to knowledge of the company)Qaz - It was interesting to note in the last conference call that the breakeven level of sales had fallen from circa $7m to $4.6m pa, which implies cash burn has dropped from circa $80k pw to closer to $35k. This implies the newly raised cash may give them a 12-18 month window. Over that time it is possible they get traction on the wellness side - the market would, I suspect, richly reward even marginal success on this front, given a market cap of sub $10m.I'm disappointed management did not participate in the cash raise. It doesn't make a great deal of sense - even a token level of participation would have had an amplified impact on confidence. Perhaps they were limited for some reason or perhaps they intend purchasing in the after market. I think breath actuated tests are still a great idea - particularly when targeting a wellness market populated by health enthusiasts. With some medtechs the risk is getting the products to market - here, the risks are clearly related to trust. But nonetheless, if it works out from this valuation level and the risks are ameliorated, investors will be very well rewarded, imo dyor.
wigwammer
16/1/2017
10:23
Enjoy Transylvania.
wigwammer
14/1/2017
17:41
There is plenty of life in me; sadly you can't say the same about Walter's outfit. Just sucking money
norbus
13/1/2017
21:57
Cheer up Norbus,there's life in you yet.
algernon2
13/1/2017
13:41
Basket case
norbus
13/1/2017
10:02
"These could half again in a week". And you could make a constructive comment in a week. Strange things do sometimes happen.....
qazwsxedc69
Chat Pages: 152  151  150  149  148  147  146  145  144  143  142  141  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20170223 05:05:18